Adlai Nortye Ltd. (ANL) - Form 20-F Summary
Business Context and Reporting Period
Company: Adlai Nortye Ltd.
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: Adlai Nortye is a global clinical-stage biopharmaceutical company focused on discovering and developing innovative cancer therapies. The company operates through subsidiaries in the U.S. and mainland China, with a pipeline centered on RAS-targeting therapies (AN9025, AN4035) and next-generation cancer immunotherapies (AN8025, AN4005).
Corporate Status: Incorporated in the Cayman Islands; listed on Nasdaq (Symbol: ANL). Shareholders approved a redomiciliation to Singapore in December 2025, which was pending as of the report date.
Key Financial Metrics (2025 vs. 2024)
| Metric (in millions USD) | 2025 | 2024 | 2023 (Revised) |
|---|---|---|---|
| Revenue | $5.0 | $0.0 | $0.0 |
| Net Loss | $(35.5) | $(51.9) | $(109.2) |
| Operating Loss | $(35.7) | $(52.9) | $(72.6) |
| R&D Expenses | $(32.8) | $(44.9) | $(58.2) |
| G&A Expenses | $(8.3) | $(10.0) | $(15.3) |
| Cash Used in Operating Activities | $(33.5) | $(51.8) | $(56.7) |
| Cash and Cash Equivalents (Year End) | $8.1 | $60.9 | $91.5 |
| Total Assets | $34.4 | $71.3 | $N/A |
| Total Liabilities | $42.8 | $45.8 | $N/A |
| Shareholders' Equity (Deficit) | $(8.3) | $25.5 | $75.0 |
Note: The 2023 financial statements were revised to correct the accounting treatment of a contract liability, resulting in a $5.0 million revenue recognition in 2025 that was previously deferred.
Material Changes vs. Prior Period
- Revenue Recognition: The company recognized $5.0 million in revenue in 2025 from a contract liability. This represented a non-refundable upfront fee received in 2023 for an exclusive option to enter a license agreement. The revenue was recognized in 2025 after the related project was discontinued and the likelihood of the customer exercising remaining rights became remote.
- Expense Reduction: Net loss decreased by approximately 31.6% year-over-year. R&D expenses declined by 26.9% primarily due to major programs not yet advancing to clinical stages (lower preclinical CRO costs) and a reduction in U.S. research personnel. G&A expenses decreased by 17.0% due to lower share-based compensation expenses.
- Liquidity Position: Cash and cash equivalents decreased significantly from $60.9 million in 2024 to $8.1 million in 2025. The company moved from a net current asset position in 2024 to a net current liability position (working capital deficiency) of $14.7 million in 2025.
- Financial Liabilities: The company no longer holds financial liabilities at fair value through profit or loss (FVTPL) as preferred shares were converted to ordinary shares following the 2023 IPO, eliminating the significant fair value losses recorded in 2023.
Guidance, Outlook, and Risks
Outlook and Liquidity: The company anticipates continuing to incur significant expenses and operating losses for the foreseeable future. Management believes that proceeds from a recent collaboration agreement with Jiangsu Aosaikang Pharmaceutical Co., Ltd. (ASK Pharm) regarding AN9025, combined with a Private Investment in Public Equity (PIPE) financing expected to close in February 2026 (gross proceeds approx. $140 million), will provide sufficient liquidity for at least the next 12 months.
Key Risks and Contingencies:
- Going Concern: The filing discloses a material uncertainty regarding the company's ability to continue as a going concern due to the working capital deficiency and accumulated deficits, contingent on the successful closing of the PIPE financing and collaboration payments.
- Internal Controls: A material weakness in internal control over financial reporting was identified related to the incorrect application of accounting standards for the sale of an exclusive option. This weakness resulted in the revision of prior period financial statements and continues to exist as of December 31, 2025, though remediation efforts are underway.
- Regulatory and Clinical Risks: As a clinical-stage company, success depends on the successful development and regulatory approval of drug candidates. Risks include clinical trial failures, delays, and the inability to secure necessary regulatory approvals from the FDA, NMPA, or EMA.
- China Operations: The company faces risks related to PRC laws and regulations, including data security, foreign exchange controls, and the potential for the ADSs to be delisted under the Holding Foreign Companies Accountable Act (HFCAA) if the PCAOB cannot inspect the company's auditor.
Important Facts for Investor Verification
- Pending PIPE Financing: Verify the closing of the February 2026 PIPE financing (approx. $140 million) and the receipt of the initial $85 million gross proceeds mentioned in the filing, as this is critical to the company's stated liquidity runway.
- Redomiciliation Status: Confirm the completion status of the redomiciliation from the Cayman Islands to Singapore, approved by shareholders in December 2025.
- Internal Control Remediation: Monitor the progress of remediation for the material weakness in internal controls over financial reporting, specifically regarding the accounting for complex contracts and revenue recognition.
- Clinical Trial Milestones: Track the progress of key clinical trials, specifically the Phase I studies for AN9025 and AN8025, and the Phase II ARTEMIS study for AN0025 (topline results expected H1 2027).
- Collaboration Payments: Verify the receipt of milestone payments from the ASK Pharm collaboration for AN9025, which includes potential payments up to $230 million.